The role of endothelial cell apoptosis in the effect of etanercept in psoriasis

British Journal of Dermatology

Volumn 163, Issue 5, 2010, Pages 928-934

  Avramidis, G ^a   Kruger Krasagakis S ^a   Krasagakis, K ^a   Fragiadaki, I ^a   Kokolakis, G ^a   Tosca, A ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Bcl 2; Bcl xL; Endothelial cells; Etanercept; Nuclear factor B; Psoriasis

Indexed keywords

CD31 ANTIGEN; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; THROMBOSPONDIN 1; VASCULOTROPIN;

ADULT; ANGIOGENESIS; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; DISEASE SEVERITY; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SKIN BIOPSY; SKIN BLOOD VESSEL; TONSILLITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIGENS, CD31; APOPTOSIS; BCL-X PROTEIN; BIOPSY; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78249268523     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09935.x     Document Type: Article

References (32)

1. Barker JN,. Pathophysiology of psoriasis. Lancet 1991; 338: 227 -30.
2. Creamer D, Sullivan D, Bicknell R, et al. Angiogenesis in psoriasis. Angiogenesis 2002; 5: 231 -6.
3. Creamer D, Allen MH, Sousa EA, et al. Localization of endothelial proliferation of microvascular expansion in active plaque psoriasis. Br J Dermatol 1997; 136: 859 -65.
4. Braverman IM, Sibley J,. Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 1982; 78: 12 -17.
5. Krueger JG, Bowcock A,. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64: 30 -6.
6. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004; 6: 326 -34.
7. Cäete JD, Pablos JL, Sanmartí R, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004; 50: 1636 -41.
8. Campanati A, Goteri G, Simonetti O, et al. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol 2009; 22: 371 -7.
9. Banno T, Gazel A, Blumenberg M,. Pathway-specific profiling identifies the NF-κB dependent tumor necrosis factor α regulated genes in epidermal keratinocytes. J Biol Chem 2005; 280: 18973 -80.
10. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB,. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006; 281: 5612 -22.
11. Malaviya R, Sun Y, Tan J, et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 2006; 55: 590 -7.
12. Ilan N, Madri JA,. PECAM-1: old friend, new partners. Curr Opin Cell Biol 2003; 15: 515 -24.
13. Detmar M,. The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci 2000; 24: S78 -84.
14. Nickoloff BJ, Mitra RS, Varani J, et al. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144: 820 -8.
15. Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999; 155: 441 -52.
16. Negoescu A, Loimier P, Labat-Moleur F, et al. In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation of cell preparations. J Histochem Cytochem 1996; 44: 959 -68.
17. Garrity M, Burgart L, Riehle D, et al. Identifying and quantifying apoptosis: navigating technical pitfalls. Mod Pathol 2003; 16: 389 -94.
18. Hern S, Stanton AW, Mellor RH, et al. In vivo quantification of the structural abnormalities in psoriatic microvessels before and after pulsed dye laser treatment. Br J Dermatol 2005; 152: 505 -11.
19. Folkman J,. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27 -31.
20. Lizzul PF, Aphale A, Malaviya R, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 2005; 124: 1275 -83.
21. Takahashi H, Manabe A, Ishida-Yamamoto A, et al. Aberrant expression of apoptosis-related molecules in psoriatic epidermis. J Dermatol Sci 2002; 28: 187 -97.
22. Lowes M, Bowcock A, Krueger J,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866 -73.
23. Kruger-Krasagakis S, Galanopoulos V, Giannikaki L, et al. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br J Dermatol 2006; 154: 460 -6.
24. Markham T, Mathews C, Rogers S, et al. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy. Br J Dermatol 2006; 155: 1191 -6.
25. Senger DR, Ledbetter SR, Claffey KP, et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996; 149: 293 -305.
26. Senger DR, Claffey KP, Benes JE, et al. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1, and alpha2beta1integrins. Proc Natl Acad Sci USA 1997; 94: 13612 -17.
27. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983 -5.
28. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470 -8.
29. Henno A, Blacher S, Lambert CA, et al. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis. J Dermatol Sci 2010; 57: 162 -9.
30. Tolsma SS, Volpert OV, Good DJ,. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993; 122: 497 -511.
31. Nelson AA, Pearce DJ, Fleischer AB, et al. New treatments for psoriasis: which biologic is best? J Dermatolog Treat 2006; 17: 96 -107.
32. Heidenreich R, Röcken M, Ghoreschi K,. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009; 90: 232 -48.